Related references
Note: Only part of the references are listed.LCI699, a Potent 11β-hydroxylase Inhibitor, Normalizes Urinary Cortisol in Patients With Cushing's Disease: Results From a Multicenter, Proof-of-Concept Study
Xavier Bertagna et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
Treatment and health outcomes in adults with congenital adrenal hyperplasia
Thang S. Han et al.
NATURE REVIEWS ENDOCRINOLOGY (2014)
Plasma aldosterone levels are elevated in patients with pulmonary arterial hypertension in the absence of left ventricular heart failure: a pilot study
Bradley A. Maron et al.
EUROPEAN JOURNAL OF HEART FAILURE (2013)
Study of Aldosterone Synthase Inhibition as an Add-On Therapy in Resistant Hypertension
Adam D. Karns et al.
JOURNAL OF CLINICAL HYPERTENSION (2013)
Sequential comparison of aldosterone synthase inhibition and mineralocorticoid blockade in patients with primary aldosteronism
Laurence Amar et al.
JOURNAL OF HYPERTENSION (2013)
The Effects of Aldosterone Synthase Inhibition on Aldosterone and Cortisol in Patients With Hypertension: A Phase II, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study
Karl Andersen et al.
JOURNAL OF CLINICAL HYPERTENSION (2012)
Effects of a Novel Aldosterone Synthase Inhibitor for Treatment of Primary Hypertension Results of a Randomized, Double-Blind, Placebo- and Active-Controlled Phase 2 Trial
David A. Calhoun et al.
CIRCULATION (2011)
GPR30 Expression Is Required for the Mineralocorticoid Receptor-Independent Rapid Vascular Effects of Aldosterone
Robert Gros et al.
HYPERTENSION (2011)
Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms.
Faiez Zannad et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Minireview: Aldosterone and Mineralocorticoid Receptors: Past, Present, and Future
John W. Funder
ENDOCRINOLOGY (2010)
Aldosterone Synthase Inhibition With LCI699 A Proof-of-Concept Study in Patients With Primary Aldosteronism
Laurence Amar et al.
HYPERTENSION (2010)
Aldosterone: effects on the kidney and cardiovascular system
Marie Briet et al.
NATURE REVIEWS NEPHROLOGY (2010)
Aldosterone and inflammation
Kimberly C. Gilbert et al.
CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY (2010)
Aldosterone Antagonists for Preventing the Progression of Chronic Kidney Disease: A Systematic Review and Meta-analysis
Sankar D. Navaneethan et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2009)
New aspects of rapid aldosterone signaling
C. Grossmann et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2009)
Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS)
Bertram Pitt et al.
CIRCULATION (2008)
Adoption of spironolactone therapy for older patients with heart failure and left ventricular systolic dysfunction in the United States, 1998-2001
FA Masoudi et al.
CIRCULATION (2005)
Aldosterone nongenomically worsens ischemia via protein kinase C-dependent pathways in hypoperfused canine hearts
M Fujita et al.
HYPERTENSION (2005)
Aldosterone biosynthesis, regulation, and classical mechanism of action
G Williams
HEART FAILURE REVIEWS (2005)
Rates of hyperkalemia after publication of the randomized aldactone evaluation study
DN Juurlink et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction
B Pitt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Beneficial neurohormonal profile of spironolactone in severe congestive heart failure -: Results from the RALES neurohormonal sub-study
MF Rousseau et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2002)
Mechanisms of disease - Aldosterone in congestive heart failure
KT Weber
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Share Paper
